{"pmid":32437961,"title":"Coagulation changes and thromboembolic risk in COVID-19 pregnant patients.","text":["Coagulation changes and thromboembolic risk in COVID-19 pregnant patients.","Anaesth Crit Care Pain Med","Benhamou, Dan","Keita, Hawa","Bouthors, Anne Sophie","32437961"],"journal":"Anaesth Crit Care Pain Med","authors":["Benhamou, Dan","Keita, Hawa","Bouthors, Anne Sophie"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437961","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.accpm.2020.05.003","keywords":["(haemorrhage)","coagulation","fibrinolysis","hypercoagulability","pregnancy","regional anaesthesia"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667521393725538304,"score":9.490897,"similar":[{"pmid":32428809,"title":"Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.","text":["Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.","Med Hypotheses","Magro, Giuseppe","32428809"],"journal":"Med Hypotheses","authors":["Magro, Giuseppe"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428809","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.mehy.2020.109829","keywords":["covid-19","coagulation","coagulation disorder","coagulopathy","cytokine storm","cytokines","heparin","lmwh","sars-cov-2"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728912789506,"score":69.61995},{"pmid":32304581,"title":"Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis.","text":["Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis.","Coronavirus disease 2019 (COVID-19) is widely spread and poses a critical threat to global health (Zhang et al). Prominent changes in coagulation function in severe patients of COVID-19 have been reported in a recent study (Han, et al 2020). Therefore, we conducted this quantitative meta-analysis to explore the difference in blood coagulation parameters between severe and mild cases of COVID-19.","Br J Haematol","Xiong, Mi","Liang, Xue","Wei, You-Dong","32304581"],"abstract":["Coronavirus disease 2019 (COVID-19) is widely spread and poses a critical threat to global health (Zhang et al). Prominent changes in coagulation function in severe patients of COVID-19 have been reported in a recent study (Han, et al 2020). Therefore, we conducted this quantitative meta-analysis to explore the difference in blood coagulation parameters between severe and mild cases of COVID-19."],"journal":"Br J Haematol","authors":["Xiong, Mi","Liang, Xue","Wei, You-Dong"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304581","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16725","keywords":["covid-19","coagulation","coronavirus","meta-analysis","laboratory"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491042398210,"score":60.567097},{"pmid":32216698,"title":"Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility.","text":["Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility.","Patients with hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease, and kidney dysfunction have worse clinical outcomes when infected with SARS-CoV-2, for unknown reasons. The purpose of this review is to summarize the evidence for the existence of elevated plasmin(ogen) in COVID-19 patients with these comorbid conditions. Plasmin, and other proteases, may cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe patients. The plasmin(ogen) system may prove a promising therapeutic target for combating COVID-19.","Physiol Rev","Ji, Hong-Long","Zhao, Runzhen","Matalon, Sadis","Matthay, Michael A","32216698"],"abstract":["Patients with hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease, and kidney dysfunction have worse clinical outcomes when infected with SARS-CoV-2, for unknown reasons. The purpose of this review is to summarize the evidence for the existence of elevated plasmin(ogen) in COVID-19 patients with these comorbid conditions. Plasmin, and other proteases, may cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe patients. The plasmin(ogen) system may prove a promising therapeutic target for combating COVID-19."],"journal":"Physiol Rev","authors":["Ji, Hong-Long","Zhao, Runzhen","Matalon, Sadis","Matthay, Michael A"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32216698","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1152/physrev.00013.2020","keywords":["covid-19","sars-cov-2","comorbidity","fibrinolysis","plasmin(ogen)"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490504478720,"score":58.670746},{"pmid":32374029,"title":"Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis.","text":["Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis.","We present a case series of three patients with COVID-19 who developed arterial vascular complications, one who developed an acute CVA, one who developed popliteal artery occlusion and one who developed both during their hospital course. We present a case series of three patients admitted to Northwell Plainview Hospital in Plainview, New York with COVID-19 as confirmed by PCR. The clinical disease course of COVID-19 has been well documented in China and Europe and most recently, the United States. Publications highlighting the non-respiratory complications of COVID-19 have been limited.[1, 2] Acute cardiac injury and arrhythmia in the ICU have been described as major complications of COVID-19.[3] A few publications have highlighted the incidence of venous thromboembolic complications in COVID-19.[4, 5].","Br J Haematol","Griffin, Daniel O","Jensen, Alexandra","Khan, Mushmoom","Chin, Jessica","Chin, Kelly","Parnell, Ryan","Awwad, Christopher","Patel, Darshan","32374029"],"abstract":["We present a case series of three patients with COVID-19 who developed arterial vascular complications, one who developed an acute CVA, one who developed popliteal artery occlusion and one who developed both during their hospital course. We present a case series of three patients admitted to Northwell Plainview Hospital in Plainview, New York with COVID-19 as confirmed by PCR. The clinical disease course of COVID-19 has been well documented in China and Europe and most recently, the United States. Publications highlighting the non-respiratory complications of COVID-19 have been limited.[1, 2] Acute cardiac injury and arrhythmia in the ICU have been described as major complications of COVID-19.[3] A few publications have highlighted the incidence of venous thromboembolic complications in COVID-19.[4, 5]."],"journal":"Br J Haematol","authors":["Griffin, Daniel O","Jensen, Alexandra","Khan, Mushmoom","Chin, Jessica","Chin, Kelly","Parnell, Ryan","Awwad, Christopher","Patel, Darshan"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374029","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16792","keywords":["covid-19","sars-cov2","hypercoagulability","pulmonary embolism","thromboembolic"],"locations":["Plainview","New York","China","United States"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138496393281540,"score":57.11433},{"pmid":32502594,"title":"Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.","text":["Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.","BACKGROUND: Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of Trials were systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. RESULTS: The systematic review and critical analysis of the literature based on13 PICO questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. CONCLUSIONS: The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving.","Chest","Moores, Lisa K","Tritschler, Tobias","Brosnahan, Shari","Carrier, Marc","Collen, Jacob F","Doerschug, Kevin","Holley, Aaron B","Jimenez, David","LeGal, Gregoire","Rali, Parth","Wells, Philip","32502594"],"abstract":["BACKGROUND: Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. METHODS: A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of Trials were systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. RESULTS: The systematic review and critical analysis of the literature based on13 PICO questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. CONCLUSIONS: The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving."],"journal":"Chest","authors":["Moores, Lisa K","Tritschler, Tobias","Brosnahan, Shari","Carrier, Marc","Collen, Jacob F","Doerschug, Kevin","Holley, Aaron B","Jimenez, David","LeGal, Gregoire","Rali, Parth","Wells, Philip"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502594","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.chest.2020.05.559","keywords":["covid-19","dic","deep vein thrombosis","hypercoagulability","pulmonary embolism","venous thromboembolism"],"locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1668804508871819264,"score":54.62465}]}